The association between TLR2/4 and clinical outcome in intracerebral hemorrhage

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Clinical Neurology and Neurosurgery Pub Date : 2024-07-08 DOI:10.1016/j.clineuro.2024.108440

Chunyan Lei, Keyang Chen, Yu Gu, Yongyu Li, Xiaoyan Zhu, Haijiang Li, Ruohong Xue, Xiaolong Chang, Xinglong Yang

{"title":"The association between TLR2/4 and clinical outcome in intracerebral hemorrhage","authors":"Chunyan Lei, Keyang Chen, Yu Gu, Yongyu Li, Xiaoyan Zhu, Haijiang Li, Ruohong Xue, Xiaolong Chang, Xinglong Yang","doi":"10.1016/j.clineuro.2024.108440","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and purpose</h3><p>Toll-like receptors (TLRs) are involved in innate immunity and inflammatory responses in various diseases. Our study aimed to investigate the association between the levels of soluble TLR4 (sTLR4) and soluble TLR2 (sTLR2) and clinical outcomes following intracerebral hemorrhage (ICH).</p></div><div><h3>Methods</h3><p>Patients admitted to department of Neurology with acute ICH were included. Plasma levels of sTLR4 and sTLR2 after ICH were measured by enzyme-linked immunosorbent assay. Poor clinical outcome was defined as a modified Rankin score (mRS) of 3–6 at 3-month and 12-month after onset.</p></div><div><h3>Results</h3><p>All 207 patients with ICH and 100 non-stroke controls were included in our analysis. The mean sTLR4 level was 4.53±1.51 ng/ml and mean sTLR2 level was 3.65±0.72 ng/ml. There was significant trend towards worse clinical outcomes with increasing sTLR4 and sTLR2 terciles at 3 and 12 months. According to receiver operating curve (ROC), the sTLR4 was reliable predictor for poor clinical outcome at 3 months (ROC=0.75) and 12 months (ROC=0.74). The sTLR2 was less reliable predictor for poor clinical outcome at 3 months (ROC=0.64) and 12 months (ROC=0.65). The level of sTLR4 was an independent predictor of poor clinical outcome at 12-month (OR 1.24, 95 % CI 1.16–1.80; <em>P</em>=0.019).</p></div><div><h3>Conclusions</h3><p>The sTLR4 quantification may provide accurate prognostic information after ICH.</p></div>","PeriodicalId":10385,"journal":{"name":"Clinical Neurology and Neurosurgery","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurology and Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0303846724003275","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose

Toll-like receptors (TLRs) are involved in innate immunity and inflammatory responses in various diseases. Our study aimed to investigate the association between the levels of soluble TLR4 (sTLR4) and soluble TLR2 (sTLR2) and clinical outcomes following intracerebral hemorrhage (ICH).

Methods

Patients admitted to department of Neurology with acute ICH were included. Plasma levels of sTLR4 and sTLR2 after ICH were measured by enzyme-linked immunosorbent assay. Poor clinical outcome was defined as a modified Rankin score (mRS) of 3–6 at 3-month and 12-month after onset.

Results

All 207 patients with ICH and 100 non-stroke controls were included in our analysis. The mean sTLR4 level was 4.53±1.51 ng/ml and mean sTLR2 level was 3.65±0.72 ng/ml. There was significant trend towards worse clinical outcomes with increasing sTLR4 and sTLR2 terciles at 3 and 12 months. According to receiver operating curve (ROC), the sTLR4 was reliable predictor for poor clinical outcome at 3 months (ROC=0.75) and 12 months (ROC=0.74). The sTLR2 was less reliable predictor for poor clinical outcome at 3 months (ROC=0.64) and 12 months (ROC=0.65). The level of sTLR4 was an independent predictor of poor clinical outcome at 12-month (OR 1.24, 95 % CI 1.16–1.80; P=0.019).

Conclusions

The sTLR4 quantification may provide accurate prognostic information after ICH.

查看原文本刊更多论文

TLR2/4 与脑出血临床预后的关系

背景和目的类托尔受体（TLRs）参与多种疾病的先天免疫和炎症反应。我们的研究旨在探讨可溶性 TLR4（sTLR4）和可溶性 TLR2（sTLR2）的水平与脑内出血（ICH）后临床结局之间的关系。采用酶联免疫吸附法测定 ICH 后血浆中 sTLR4 和 sTLR2 的水平。在发病后 3 个月和 12 个月，改良 Rankin 评分（mRS）达到 3-6 分即为临床预后不良。平均 sTLR4 水平为 4.53±1.51 纳克/毫升，平均 sTLR2 水平为 3.65±0.72 纳克/毫升。在 3 个月和 12 个月时，随着 sTLR4 和 sTLR2 三分位数的增加，临床结果呈明显的恶化趋势。根据接收器操作曲线（ROC），sTLR4 是预测 3 个月（ROC=0.75）和 12 个月（ROC=0.74）不良临床预后的可靠指标。在 3 个月（ROC=0.64）和 12 个月（ROC=0.65）时，sTLR2 对不良临床结果的预测不那么可靠。结论 sTLR4 定量可为 ICH 后提供准确的预后信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neurology and Neurosurgery 医学-临床神经学

CiteScore

3.70

自引率

5.30%

发文量

358

审稿时长

46 days

期刊介绍： Clinical Neurology and Neurosurgery is devoted to publishing papers and reports on the clinical aspects of neurology and neurosurgery. It is an international forum for papers of high scientific standard that are of interest to Neurologists and Neurosurgeons world-wide.